Liquidia
LQDAMarket price data through November 12, 2026.
Performance
Nov 2021 – Nov 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- +25%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$47
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- February 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 9 months
- How long Benson has been tracking this pick.
About Liquidia
Liquidia is a biotech company built around Yutrepia, an inhaled powder for pulmonary arterial hypertension. In this rare disease the arteries in the lungs get narrow and stiff, which strains the heart and makes every breath harder. Its patented particle technology sends the medicine deep into the lungs from a palm-sized device, and Yutrepia now brings in more than 220 million dollars a quarter just 16 months after its June 2025 launch.
The case for and against
Both sides of the story, in plain English.
- Sales Sprint
Yutrepia sales hit 222.7 million dollars in the third quarter of 2026. That is up 31 percent from the second quarter and more than four times the 51.7 million from a year ago. Leaving out the one-time legal bill, its core earnings grew for a fifth straight quarter to 140.5 million dollars, and October was its biggest month for shipments since launch.
- Clear Runway
Liquidia settled all six lawsuits with rival United Therapeutics, so Yutrepia stays available and no current patient has to stop. Its main market looks strong: in September more than 70 percent of new referrals were for pulmonary arterial hypertension, and 1,300 doctors now prescribe it. Cash reached 396.1 million dollars before the settlement payments, about double where it started the year.
- Costly Peace
Ending the court fight came with a big bill. Liquidia agreed to pay a net 380.7 million dollars across 2026 and 2027, and a 389.7 million dollar charge turned the quarter into a 236.3 million dollar loss. It also agreed to drop its second approved use, for patients with scarred lungs, giving up a US group estimated at more than 60,000 people.
- Referral Cooldown
In October, as Liquidia stopped marketing Yutrepia for scarred lungs, new patient referrals per day ran at just over 75 percent of the third quarter pace. Costs keep rising too: research spending jumped 170 percent to 25.3 million dollars, and sales and overhead rose 47 percent to 59 million. Almost all of its money comes from one drug, so any slowdown would hurt fast.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-11-12. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch LQDA for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.